Cargando…

Renal Effects of SGLT2 Inhibitors and Potential Clinical Implications: Beyond the Heart

Detalles Bibliográficos
Autor principal:	Lee, Sunki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Heart Failure 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634024/ https://www.ncbi.nlm.nih.gov/pubmed/36381015 http://dx.doi.org/10.36628/ijhf.2022.0017

Ejemplares similares

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

The anti-inflammatory effects of SGLT inhibitors
por: García-Ropero, Álvaro, et al.
Publicado: (2019)

SGLT2 Inhibitors: the Gift that Keeps on Giving
por: Garcia, Maria Victoria Faith, et al.
Publicado: (2021)

SGLT2 Inhibitors: Statins or ACE-Inhibitors of the 21st Century?
por: Correale, Michele, et al.
Publicado: (2023)

Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
por: Youssef, Mahmoud E., et al.
Publicado: (2023)

Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
por: Palmiero, Giuseppe, et al.
Publicado: (2021)

Evolving insights into the pleiotropic cardioprotective mechanisms of SGLT2 inhibitors
por: Fender, Anke C., et al.
Publicado: (2023)

Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease
por: Hwang, Jiwon, et al.
Publicado: (2020)

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
por: Kanduri, Swetha R., et al.
Publicado: (2020)

Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?
por: Nomiyama, Takashi
Publicado: (2020)

Editorial to the IJMS Special Issue on Sglt2 Inhibitors Vol. 1
por: Lymperopoulos, Anastasios
Publicado: (2023)

Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure
por: Oh, Chang-Myung, et al.
Publicado: (2019)

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
por: Androutsakos, Theodoros, et al.
Publicado: (2022)

The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
por: Ji, Peng‐juan, et al.
Publicado: (2023)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

SGLT2 INHIBITORS - SOMETHING IN THE WATER, OR THE HEART OF THE MATTER?
por: Esmonde, S, et al.
Publicado: (2020)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

SGLT2 Inhibitors as Potential Anticancer Agents
por: Basak, Debasish, et al.
Publicado: (2023)

Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes
por: Gronda, Edoardo G., et al.
Publicado: (2022)

COP27 Climate Change Conference Editorial, TAVI, SGLT2 inhibitors…
por: Erol, Çetin
Publicado: (2022)

SGLT2i: beyond the glucose-lowering effect
por: Ni, Lihua, et al.
Publicado: (2020)

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
por: Pabel, Steffen, et al.
Publicado: (2021)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

Hereditary renal glycosuria, diabetes and responses to SGLT2 inhibitor
por: Ren, Qian, et al.
Publicado: (2022)

SGLT2 inhibitors and renal complications in type 1 diabetes
por: Petrie, John R
Publicado: (2020)

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
por: Bailey, Clifford J., et al.
Publicado: (2022)

Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers
por: Gessner, Arne, et al.
Publicado: (2022)

Neuroprotective Effect of SGLT2 Inhibitors
por: Pawlos, Agnieszka, et al.
Publicado: (2021)

Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
por: Ogawa, Wataru, et al.
Publicado: (2015)

SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D
por: Escalada, Javier
Publicado: (2022)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Complementary actions of finerenone and SGLT2‐i on renal outcomes?: An urgent need for more information
por: Rebelos, Eleni, et al.
Publicado: (2022)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
por: Frąk, Weronika, et al.
Publicado: (2023)

Is There a Diabetes–Kidney–Heart Continuum? Perspectives From the Results of the Cardiovascular and Renal Outcome Clinical Trials With SGLT2 Inhibitors
por: Bao, Liwen, et al.
Publicado: (2021)

SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
por: Wilding, John, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mtsoapn963p1kg3s81qbftaolr